Sanofi (SNY) Fundamental Analysis: Revenue, Earnings & Valuation

2.64 / 10

Underperform

Fundamentals are underperforming (2.6/10). Days sales outstanding and cost‑of‑sales ratio are modest strengths, while the current ratio and operating‑revenue growth are weak, leading to a guarded outlook.

Analysis Checks(6/10)

Total operating revenue (YoY growth rate %)

Value5.49

Score1/3

Weight0.47%

1M Return0.17%

Days sales outstanding

Value66.37

Score2/3

Weight3.16%

1M Return1.06%

PB-ROE

Value-0.12

Score2/3

Weight40.37%

1M Return10.57%

Income tax / Total profit (%)

Value17.33

Score3/3

Weight15.85%

1M Return4.62%

Total profit / EBIT (%)

Value97.27

Score3/3

Weight2.92%

1M Return0.94%

Interest coverage ratio (EBIT / Interest expense) (%)

Value36.62

Score2/3

Weight-0.88%

1M Return-0.31%

Operating revenue (YoY growth rate %)

Value6.20

Score1/3

Weight0.27%

1M Return0.10%

Cost of sales ratio (%)

Value29.91

Score3/3

Weight4.16%

1M Return1.27%

Asset-MV

Value-0.55

Score1/3

Weight40.64%

1M Return9.37%

Current ratio

Value1.09

Score0/3

Weight-6.94%

1M Return-2.54%

Is SNY undervalued or overvalued?

SNY scores 2.64/10 on fundamentals and holds a Premium valuation at present. Backed by its 10.45% ROE, 16.81% net margin, 12.33 P/E ratio, 1.34 P/B ratio, and 63.43% earnings growth, these metrics solidify its Underperform investment rating.